|
1) 大田 健. マスト細胞と好塩基球～基礎編～. 分子呼吸器病. 2000; 4: 229-33
|
|
|
|
2) Heusser C, Jardeu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol. 1997; 9: 805-13
|
|
|
|
|
3) Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997; 155: 1828-34
|
|
|
|
|
|
4) Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108: 184-90
|
|
|
|
|
|
5) Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001; 18: 254-61
|
|
|
|
|
|
6) Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-elated morbidity and mortality. Current Med Research and Opinion. 2001; 17: 233-40
|
|
|
|
|
|
7) 大田 健, 監修. In: GINA2006《日本語版》. 東京: 協和企画; 2006. p. 54-6
|
|
|
|
|
|
8) Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000; 356: 2144-8
|
|
|
|
|
|
9) Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized placebo-controlled trial. Am J Respir Crit Care Med. 1999; 160: 1816-23
|
|
|
|
|
|
10) Bryan S, O'Connor B, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperresponsiveness, and the late asthmatics response. Lancet. 2000; 356: 2149-53
|
|
|
|
|
|
11) Howarth PH, Babu KS, Arshad HS, et al. Tumor necrosis factor-alpha (TNF-alpha) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax. 2005; 60: 1012-8
|
|
|
|
|
|
12) Busse WW, Baker JW, Charous BL, et al. Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma [abstract]. J Allergy Clin Immunol. 2004; 113: S286-7
|
|
|
|
|